Computationally repurposing drugs for breast cancer subtypes using a network-based approach

BMC Bioinformatics

Table 4 Top 20 drugs corresponding to subtype 3

Rank	Drug	Dosage (μm)	Treatment time (h)	Score	Drug type	References
1	Bromocriptine	0.04	24	− 0.72	Approved	[63]
2	Ruxolitinib	10	24	− 0.68	Approved	[51, 52]
3	Deferiprone	0.04	24	− 0.62	Approved	[66, 67]
4	Tadalafil	10	24	− 0.61	Approved
5	Sirolimus	0.04	24	− 0.58	Approved	[71, 72]
6	Rupatadine	0.04	24	− 0.58	Approved
7	Ribavirin	10	24	− 0.57	Approved	[65]
8	Pha-767491	10	24	− 0.57	Experimental	[83]
9	Etofylline-Clofibrate	10	24	− 0.57	Approved
10	EDTA	10	24	− 0.56	Approved	[93]
11	Tranilast	0.04	24	− 0.56	Investigational	[68]
12	MK-1775	10	24	− 0.56	Investigational	[77]
13	Raclopride	10	24	− 0.54	Investigational
14	Iniparib	10	24	− 0.54	Investigational	[80]
15	Bexarotene	10	24	− 0.54	Approved	[94]
16	PF-04217903	0.04	24	− 0.54	Investigational
17	Swainsonine	0.05	24	− 0.53	Experimental	[95]
18	JTC-801	0.04	24	− 0.53	Experimental	[96]
19	Ofloxacin	10	24	− 0.53	Approved	[97]
20	Mibampator	0.04	24	− 0.52	Investigational

ISSN: 1471-2105